Harvard Bioscience Inc
Company Profile
Business description
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
Contact
84 October Hill Road
Suite 10
HollistonMA01746
USAT: +1 508 893-8999
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
339
Stocks News & Analysis
stocks
ASX giant falls short on copper guidance
stocks
Pure-play data center share raises capital to fund AI demand
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,998.20 | 8.90 | -0.10% |
| CAC 40 | 8,338.81 | 39.05 | -0.47% |
| DAX 40 | 24,830.98 | 84.51 | -0.34% |
| Dow JONES (US) | 52,146.42 | 406.55 | -0.77% |
| FTSE 100 | 10,600.37 | 28.13 | 0.27% |
| HKSE | 25,072.77 | 510.53 | 2.08% |
| NASDAQ | 25,520.24 | 361.70 | -1.40% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,703.00 | 8.32 | 0.06% |
| S&P 500 | 7,457.69 | 76.08 | -1.01% |
| S&P/ASX 200 | 8,814.40 | 7.90 | -0.09% |
| SSE Composite Index | 3,808.39 | 44.23 | 1.18% |